Are Dry Herb Vaporisers Safe? What the Science Says in 2026

In February 2025, the journal Cannabis and Cannabinoid Research published what may be the most significant clinical guidance document for cannabis vaporisation to date. MacCallum, Lo, and Boivin's comprehensive best-practices guide formally recommends dried cannabis vaporisers and metered-dose inhalers over other vaporisation devices — the first peer-reviewed clinical guide to make this recommendation explicitly.^[1] The paper positions dry herb vaporisation as safe for fast-acting cannabinoid administration and as a legitimate harm reduction tool, while emphasising the importance of regulated, third-party tested products.

That paper did not appear in isolation. It arrived alongside a growing body of evidence — from inflammatory marker studies to vapour composition analyses — that continues to refine the picture of what dry herb vaporisation does and does not do to the body. This article examines that evidence, addresses the most persistent misconceptions, and states clearly where uncertainty remains.

How Vaporisation Differs From Combustion

When cannabis is combusted — in a joint, pipe, or bong — temperatures exceed 400°C. At those temperatures, the plant material undergoes pyrolysis, producing over 100 chemical compounds including carcinogenic polycyclic aromatic hydrocarbons (PAHs), carbon monoxide, benzene, and toluene.^[2] The user inhales the target cannabinoids alongside this cocktail of combustion byproducts.

Vaporisation heats cannabis to between 170°C and 210°C (338–410°F) — below the combustion threshold. At these temperatures, cannabinoids and terpenes become volatile and enter the vapour stream, but the conditions required for pyrolysis are not met. The MAPS/Cal-NORML Volcano study — still the gold-standard vapour composition analysis — found that at 200°C, the vapour consisted of approximately 95% cannabinoids (principally THC and CBN), with the remaining 5% comprising only trace compounds.^[2] Benzene, toluene, and naphthalene were completely eliminated at this temperature.^[2]

This is not a marginal difference. The comparison between 95% cannabinoids with minimal trace compounds versus 100+ chemical byproducts including known carcinogens represents a fundamental difference in what the user inhales. For a detailed exploration of this distinction and its implications for nicotine vaping and concentrate devices, see Dry Herb vs Extracts vs E-Liquid.

What the Research Shows: Respiratory Health

The Inflammatory Oxylipin Finding

A 2024 study examining inflammatory markers in the airways of different user groups produced one of the most striking findings in recent vaporisation research.^[3] The study measured inflammatory oxylipins — biomarkers associated with airway inflammation — and found that THC vaporiser users had inflammatory profiles closer to non-users than to tobacco users. Tobacco users showed significant up-regulation of inflammatory oxylipins; THC vaporiser users did not.^[3]

This does not mean vaporisation has no respiratory effect — absence of elevated inflammatory markers in one study is not proof of complete safety. But it is a strong data point against the assumption that inhaling any vapour must produce tobacco-like inflammatory responses.

The Foundational Studies

The Hazekamp et al. (2006) Volcano study established that optimal vaporisation at 200°C produced no detectable pyrolysis products — no combustion byproducts, no unexpected chemical compounds — with higher cannabinoid delivery efficiency than smoking.^[4] The Abrams et al. (2007) comparative study of 18 inpatient subjects found similar THC bioavailability between vaporised and smoked cannabis, with dramatically reduced carbon monoxide exposure in the vaporised group.^[5] Cannabis-only users have shown no evidence of lung function impairment in epidemiological data, contrasting with the well-documented decline associated with cigarette smoking.^[6]

Limitations in the Evidence

A systematic review and meta-analysis covering evidence from July 2021 to December 2023 found that non-smoker vapers (across all vaping categories) showed a higher risk of respiratory symptoms (relative risk 1.90, 95% CI: 1.28–2.83), though the risk of COPD was non-significant.^[7] Critically, this review covers all forms of vaping — not dry herb specifically — and the aggregation of nicotine e-cigarettes, concentrate devices, and dry herb vaporisers within the same analysis limits the conclusions that can be drawn for any single category.

Most vaporisation studies are short-term. Five-to-ten-year longitudinal data specifically for dry herb vaporisation is limited. The long-term effects of daily inhalation of cannabinoid-rich vapour — even vapour with a favourable composition profile — remain an acknowledged research gap.

Temperature and Safety

The relationship between temperature and safety is well-defined at the extremes and less precise in the middle range. Below 230°C (446°F), the available evidence indicates that dry herb vaporisation operates within a safety threshold where harmful compound formation is minimal to absent.^[2] At 200°C, the MAPS/NORML study found complete elimination of benzene, toluene, and naphthalene. Above 230°C, the risk of PAH production and cannabinoid degradation increases, though the exponential increase in harmful compound formation occurs primarily above 400°C.

For a detailed analysis of how temperature affects terpene and cannabinoid extraction, see Cannabis Terpenes & Temperature. For hardware and materials considerations, see Vaporiser Materials & Airpath Safety.

EVALI: What It Was and What It Was Not

The EVALI (e-cigarette or vaping product use–associated lung injury) outbreak of 2019–2020 produced 2,807 hospitalisations and at least 68 deaths in the United States.^[8] The cause was identified as vitamin E acetate — a thickening agent found in 94% of bronchoalveolar lavage samples from confirmed cases — used in illicit THC oil cartridges sold through unregulated channels.^[9] Eighty-two per cent of hospitalised patients reported using THC-containing products from informal sources.^[8]

Dry herb vaporisers were not implicated. Not a single confirmed EVALI case was traced to dry herb vaporisation.^[8] This outcome is mechanistically predictable: dry herb vaporisation involves no liquids, no carrier oils, and no thickening agents. There is no medium to which vitamin E acetate could be added.

Despite this, media conflation between "vaping" categories persists.^[10] The assumption that EVALI data applies to dry herb devices is not supported by the epidemiological evidence and should be corrected wherever it is encountered.

Common Misconceptions

"All vaporisers are equally safe." This is false. Device type is a critical determinant of safety. MacCallum et al. (2024) explicitly identified dried product vaporisers and metered-dose inhalers as the lowest-risk categories, distinguishing them from concentrate devices and nicotine e-cigarettes.^[11] The materials used, the air path design, the temperature control accuracy, and the manufacturing quality all influence the safety profile of a given device.

"Vaping is completely safe." This is false. "Safer than smoking" is not the same as "safe." Current evidence strongly supports vaporisation as a harm reduction strategy for cannabis users who would otherwise smoke, but the long-term effects of daily use are not yet fully characterised. "Current evidence suggests" is the appropriate framing, not "science proves."

"EVALI proves vaporisers are dangerous." This is false. EVALI was caused by a specific adulterant (vitamin E acetate) in a specific product category (illicit THC oil cartridges). The evidence does not apply to dry herb devices.

"Popcorn lung is a risk of vaping." Bronchiolitis obliterans ("popcorn lung") is caused by diacetyl, a flavouring agent used in some nicotine e-liquids. Diacetyl does not exist in raw cannabis flower and is not produced during dry herb vaporisation. This is among the most persistent misconceptions and is entirely inapplicable to dry herb devices.

"High THC concentrates are safe in any vaporiser." This requires nuance. Concentrates eliminate combustion byproducts, but products reaching 95%+ THC have unknown long-term effects. The safety profile of concentrates also depends on extraction method, purging quality, and the potential for residual solvents — variables that do not apply to whole-flower vaporisation.

What the Research Says vs What the Headlines Claim

The gap between what the clinical evidence actually shows and what reaches the public through media coverage is one of the most persistent problems in this field. A summary of the key disconnections:

The headline: "Vaping causes lung disease." The evidence: EVALI was caused by vitamin E acetate in illicit THC oil cartridges. Dry herb vaporisation was not implicated in a single confirmed case. The blanket term "vaping" in headlines conflates three entirely different technologies.^[10]

The headline: "Vaping is 95% safer than smoking." The evidence: The PHE 95% figure was an expert opinion estimate about nicotine e-cigarettes specifically, not an empirical measurement, and not about cannabis.^[11] The figure cannot be transferred to cannabis vaporisation — different active compounds, different chemistry, different delivery medium. Cannabis vaporisation has its own evidence base, and it is strong on its own terms.

The headline: "Popcorn lung from vaping." The evidence: Bronchiolitis obliterans is caused by diacetyl, a synthetic flavouring compound. Diacetyl does not exist in raw cannabis flower and is not produced during dry herb vaporisation. The concern applies to certain flavoured nicotine e-liquids and has no relevance to dry herb devices.

The headline: "Cannabis vaping produces tissue-destroying chemical." The evidence: The 2025 CBD-Q finding relates to CBD oxidation in liquid vaporisation conditions, not in whole-flower dry herb devices. See the emerging research section below for the full context.

The Risk Spectrum

Risk is not binary. The available evidence supports a spectrum, not a division into "safe" and "dangerous":

Combustion (smoking) represents the highest-risk delivery method for inhaled cannabis. Over 100 chemical byproducts, including known carcinogens, are produced alongside the target cannabinoids. Carbon monoxide exposure is significant. Sidestream smoke affects bystanders.

Concentrate vaporisation eliminates combustion byproducts but introduces variables including potential residual solvents, very high operating temperatures (up to 470°C), and unknown long-term effects of inhaling 95%+ THC concentrations. The EVALI crisis demonstrated the extreme end of what can go wrong with unregulated concentrate products.

Dry herb vaporisation has the most favourable evidence profile among inhaled methods. Vapour composition of approximately 95% cannabinoids at 200°C, no detected combustion byproducts at recommended temperatures, inflammatory profiles in users closer to non-users than tobacco users, and a 2025 clinical recommendation as the preferred vaporisation method.

Non-use carries no inhalation risk. No harm reduction strategy eliminates risk to zero — it reduces risk relative to a higher-risk behaviour.

This spectrum should inform the way users think about their choices. Switching from smoking to dry herb vaporisation is a substantial harm reduction step supported by clinical evidence. Claiming that dry herb vaporisation is risk-free is not supported by the evidence and should not be asserted.

Emerging Research: CBD-Q

A 2025 study from UC Merced identified cannabidiol hydroxyquinone (CBD-Q) as a compound produced when CBD is oxidised during vaporisation, describing it as highly toxic to human tissue.^[12] This is a finding worth monitoring — but its applicability to dry herb vaporisation requires careful framing.

The oxidation pathway that produces CBD-Q is associated with specific conditions more common in liquid vaporisation (CBD e-liquids and concentrate cartridges) than in the vaporisation of whole cannabis flower. The study did not examine dry herb vaporisers specifically. Including CBD-Q in the broader safety landscape is appropriate; positioning it as a demonstrated risk of dry herb vaporisation is not supported by the current evidence.

UK-Specific Context

The regulatory and clinical landscape in the United Kingdom provides additional context for these findings. Public Health England's functions have transferred to the Office for Health Improvement and Disparities (OHID) since 2021, and the Medical Cannabis Clinicians Society (MCCS) updated its best-practice prescribing guidelines in 2024–2025 — both reflecting an evolving institutional approach to cannabis-based treatments.

NHS-prescribed cannabis flower is recommended for use with a medical-grade vaporiser.^[1] The only dry herb vaporisers with published medical device certification — the Storz & Bickel Volcano Medic and Mighty+ Medic — are the devices most commonly referenced in clinical guidance, though in practice patients use a broader range of quality devices. For a comprehensive guide to UK medical cannabis access, see UK Medical Cannabis & Vaporisers — A Patient's Guide. For the distinction between "medical grade" marketing and actual medical device certification, see Medical Grade vs Medical Certified Vaporisers.

The UK's single-use vape ban, enacted in June 2025, targets disposable nicotine e-cigarettes and does not affect dry herb devices — but it reflects the broader regulatory attention being paid to vaping products and their health implications.

What This Means

The evidence base for dry herb vaporisation as a harm reduction strategy continues to strengthen. The MacCallum 2025 clinical guide, the inflammatory oxylipin data, and the now well-established vapour composition analyses collectively paint a picture of a delivery method that eliminates most combustion-related risks while preserving cannabinoid delivery efficiency.

The appropriate summary is not "dry herb vaporisation is safe" — that is an oversimplification. The appropriate summary is: current evidence indicates that dry herb vaporisation substantially reduces exposure to the harmful byproducts of combustion, produces an inflammatory profile in users closer to non-users than to tobacco smokers, and is the delivery method recommended by the most recent clinical guidance. Long-term data remains limited, and uncertainty should be acknowledged wherever it exists.

For users who will consume cannabis regardless of method, switching from smoking to dry herb vaporisation is one of the most evidence-supported harm reduction steps available.